IMMUTEP
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology. Their products include a T cell immunostimulatory factor (APC activator) for cancer chemo-immunotherapy and a therapeutic antibody for immune response modulation in cancer. The Company's technologies are based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response.
IMMUTEP
Industry:
Biotechnology Clinical Trials Health Care Pharmaceutical
Founded:
1987-05-21
Address:
Sydney, New South Wales, Australia
Country:
Australia
Website Url:
http://www.immutep.com
Total Employee:
11+
Status:
Active
Contact:
+33169289992
Total Funding:
19.05 M AUD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Apache Euro
Similar Organizations
Atlantic Healthcare
A rare disease pharmaceutical company acquiring, developing and commercializing therapeutics, specializing in gastroenterology.
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
CF PharmTech
CF PharmTech is a specialty pharmaceutical company that develops and manufactures inhalation products.
Complix
Complix is a biopharmaceutical company developing Alphabodies, a novel class of biopharmaceuticals.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Gmax Biopharm
Gmax Biopharm dvelope innovative GPCR Antibody therapeutics for unmet medical use.
HealthMatch
HealthMatch connects patients with revolutionary drugs and cures.
IceCure Medical Ltd.
IceCure is a medical device company setting new standards in minimally-invasive tumor therapy women’s health and interventional oncology.
Innocare
InnoCare is a Chinese biopharmaceutical company that develops treatment for cancer and autoimmune diseases.
Oncopeptides
Oncopeptides AB is a privately held clinical stage company developing melflufen, a peptidase potentiated therapy for multiple myeloma.
OneOme
OneOme is a collaborative concern between the business builder .
IVERIC bio
IVERIC bio is a biopharmaceutical company developing novel therapies for age-related macular degeneration.
Promontory Therapeutics
Promontory Therapeutics is a clinical-stage pharmaceutical company focused on novel therapeutics in oncology.
Vaccinex
Vaccinex is a biotechnology company engaged in the development of novel therapeutic antibodies for neurodegenerative disorders and oncology.
Vesselon
Vesselon is a medical device company developing novel therapeutic Immuno-Oncology complexes.
Prescient Therapeutics
Prescient Therapeutics is a biopharmaceutical company, discovers and develops novel immunotherapeutic products for the treatment of chronic.
Current Employees Featured
Marc Voigt CEO @ Immutep
CEO
Frédéric Triebel CSO and CMO @ Immutep
CSO and CMO
2014-12-01
Deanne Miller General Counsel and Company Secretary @ Immutep
General Counsel and Company Secretary
2012-10-01
Founder
Stock Details
Investors List
Australian Ethical Investment
Australian Ethical Investment investment in Post-IPO Equity - Immutep
Altium Capital
Altium Capital investment in Post-IPO Equity - Immutep
Platinum AM
Platinum AM investment in Post-IPO Equity - Immutep
Official Site Inspections
http://www.immutep.com Semrush global rank: 4.05 M Semrush visits lastest month: 3.02 K
- Host name: dd32834.kasserver.com
- IP address: 85.13.133.184
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Immutep"
Company Overview - Immutep
Immutep SA - Crunchbase Company Profile & Funding
Organization. Immutep SA . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. About. Immutep is a …See details»
Immutep - Wikipedia
Immutep Ltd (formerly Prima Biomed) is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was …See details»
Immutep to Participate in Upcoming Investor Conferences - Yahoo …
20 hours ago Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, …See details»
Immutep - Crunchbase Company Profile & Funding
Immutep is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Immutep is dedicated to leveraging its technology and expertise to bring innovative …See details»
Corporate Governance Practices & Conduct Code - Immutep
Immutep Limited deanne.miller@immutep.com. Level 32, Suite 32.07 Australia Square 264 George Street, Sydney NSW 2000, Australia. auditor. PricewaterhouseCoopers One …See details»
Immutep - 2025 Company Profile, Funding & Competitors - Tracxn
Mar 26, 2025 Immutep is an acquired company based in Sydney (Australia), founded in 2001. It operates as a Developer of therapeutics for the treatment of autoimmune and oncology …See details»
Immutep (IMMP) Company Profile & Description - Stock Analysis
Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product …See details»
Immutep - businessabc.net
Mar 9, 2025 Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. ... 'Most Promising Therapeutics Company' and …See details»
Immutep Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 Immutep (formerly Prima BioMed) is a biotechnology company focused on developing autoimmune and cancer immunotherapy treatment. It develops therapeutics that …See details»
Immutep Limited (IMMP) Company Profile & Facts - Yahoo Finance
See the company profile for Immutep Limited (IMMP) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
Immutep to Participate in Upcoming Investor Conferences
17 hours ago Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the …See details»
Unlocking the power of the immune system to fight cancer and …
The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP).These slides have been prepared as a presentation …See details»
Immutep Company Profile 2025: Stock Performance & Earnings
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical …See details»
Immutep to Participate in Upcoming Investor Conferences
Feb 4, 2025 Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, …See details»
Immutep stumbles on into phase 3 - ApexOnco
Jun 27, 2024 Immutep said Keytruda outperformed historical data in low PD-L1 expressers, suggesting baseline imbalances as a possible reason. In PD-L1-high cancers 19% ORR is in …See details»
LAG-3 Immunotherapy Treatments: Cancer & Autoimmune
Discover how Immutep immunotherapy treatments are strengthening the power of patients' immune systems and being used in the fight against cancer.See details»
Immutep: A Small Company With A Pipeline Resembling Big Pharma
2 days ago Immutep's lead program, Eftilagimod Alpha, shows promising data in 1st line with NSCLC and HNSCC trials. Despite positive trial results, IMMP's financials do not reflect its …See details»
What's New | Investors & Media - Immutep
First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer. March 20th 2025. Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at …See details»
Press Releases - Immutep
Dec 16, 2018 Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 …See details»